Enzalutamide and ADT Reduce Prostate Cancer Progression Risk
Enzalutamide, an androgen receptor inhibitor, when combined with androgen deprivation therapy (ADT)  in metastatic hormone-sensitive prostate cancer, has been shown to increase progression-free survival. Most deaths related to prostate cancer are due to metastatic disease in patients who have not had, or do not respond to, hormone therapy. Read more.

Ice Chips Prevent Hyperalgesia With Oxaliplatin
Baumen et al found that oral cryotherapy with oxaliplatin infusions resulted in less cold sensitivity and a shorter duration of symptoms. The theory behind this involves oral thermal hyperalgesia, and patients who receive chemotherapy may have trouble eating and tasting. Cryotherapy is easy to use and is a very simple fix to potentially help patients receiving oxaliplatin. Read more.